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We have reviewed the literature data regarding the spectrum of tumors including solitary ﬁbrous tumor and hemangiopericytoma
with special focus on deﬁnition of the disease, discussion of the criteria for malignancy, and the key elements of standard
treatmentoflocalizeddisease.Wehavediscussedtheemergingconceptsonthetumorbiologyandthediﬀerentsystemictreatments
(chemotherapy and molecular-targeted therapies).
1.Introduction
Solitary Fibrous Tumor (SFT) constitutes a heterogeneous
group of rare spindle-cell tumors that include benign and
malignant neoplasms. Their cell of origin is still debated.
SFT is preferred by most pathologists as a better term than
“hemangiopericytoma” that gathers numerous unrelated
entities and is presently only employed by neuropathologists
[1]. We focus the present paper on the forms of this family
of tumors occurring in adult patients. There are 3 typical
primary locations: pleural, meningeal and extrathoracic soft
tissue.
2. ClassicalClinicalForms
2.1. Pleural SFT. Most of SFT (80%) are benign neoplasms.
They are most commonly diagnosed in adults aged of about
50–70 [2–4] .T h eM / Fg e n d e rr a t i oi sa b o u t1 .T h e r ei sn o
identiﬁed risk factor: no association with asbestosis, tobacco
consumption or other environmental factor. Pleurodynia,
cough, and dyspnea are the most frequent revealing symp-
toms [2–4]. Most of patients are symptomatic at the time
of diagnosis [5]. Two paraneoplastic manifestations could
be seen: paraneoplastic osteoarthropathy (pulmonary osteo-
arthropathy) and more rarely paraneoplastic hypoglycemia
(Doege-Potter syndrome) [4, 6]. In the Magdeleinat series,
o s t e o a r t h r o p a t h ya n dh y p o g l y c e m i ao c c u r r e di n4 / 6 0a n d
1/60 cases, respectively [3]. Hypoglycemia is most com-
monly associated with massive SFT (mean tumor size of
about 20cm), and about 40% of the SFT associated with
hypoglycemia are malignant [6]. The mechanism causing
this symptom is likely the tumor-producing nonsuppressible
insulin-like active substances and insulin-like growth factors
(see below). Control of the hypoglycemic episodes occurs
rapidly after complete tumor removal.
CT scan classically shows a sessile or a pedunculated
pleural mass. Calciﬁcations in the tumor could be seen
in both benign and malignant cases [5]. The mean main
diameter is about 8cm (ranged, from 1 to more than
30cm) [3, 5]. The experience with ﬂuorodeoxyglucose PET
is limited; in the Kohler report, PET seemed to be “positive”
in 3/3 malignant tumors and negative in 3/3 “benign” SFT
[5]. This tumor arises more commonly from the visceral
(80%) [3] than the parietal pleura. The vast majority of
SFT are covered by a smooth glistering capsule surface [3].
Most of the tumors are composed of uniform collagen-
forming spindle-cells, arranged in interlacing fascicles. Some
show associated myxoid changes, ﬁbrosis, hyalinization,
necrosis, or rarely focal calciﬁcations. The vascularity widely
varies. The cells are negative for any anticytokeratin and2 Sarcoma
epithelial membrane antigen, but stain in all cases with
antibodies vimentin and CD34 rarely with muscle-speciﬁc
actin. Because their morphologic pattern is not speciﬁc (the
so-called patternless pattern) and there are no distinctive
immunohistochemical or electron microscopic features, it
may be diﬃcult to separate this tumor from other spindle-
cell pleural tumors by hematoxylin-eosin staining alone [7].
The criteria for malignancy are presence of necrosis
increased mitotic activity (≥4 mitotic ﬁgures per 10 HPF),
greater cellularity, and cellular polymorphism [4]. SFT could
be considered as malignant in the presence of at least one
of these criteria [4] .M a l i g n a n tS F T st e n dt ob el a r g e ra n d
more frequently symptomatic at diagnosis. The presence of
associated pleural eﬀusion is more frequent in malignant
forms. These criteria for malignancy are still discussed.
Two of them are subjective: greater cellularity and cellular
polymorphism. About 15 [2, 8] to 35% [3, 4, 9]o fS F T
are considered malignant at the time of diagnosis and
primary treatment. Recurrences are markedly more frequent
in malignant cases [5]. The median overall survival of
benignformsis about280months (5-yearOSrate:80–90%),
whereas the median OS of malign forms is about 50–60
months (5-year OS rate: 80–90%) [8].
The cornerstone of the treatment remains the large en-
bloc resection, requiring, depending on the local extension,
pulmonary wedge resection, lobectomy, pneumonectomy,
and sometimes chest wall, diaphragm, or pericardium
resection(s) [3, 8]. Mediastinal lymph node dissection is
not indicated, as lymph node metastases are rare [3, 8].
Adjuvant treatments (radiotherapy and chemotherapy) are
not usually employed [3]. In case of local recurrence,
surgery remains the recommended option. In case of distant
metastasis or locally advanced recurrence not amenable to
surgery palliative radiotherapy and palliative chemotherapy
can be considered (see below). There is no consensus on the
type of chemotherapy treatment to employ, but, by analogy
with other forms of soft tissue sarcoma, doxorubicin ±
ifosfamide-based regimen is usually the ﬁrst choice.
2.2. Soft Tissue SFT. Soft tissue SFT is usually diagnosed
in the ﬁfth decade. The distribution is equal in both
sexes. This tumor represents less than 2% of all soft tissue
tumors. Symptoms are not speciﬁc. SFT typically appears
as a slowly enlarging painless mass. Hypoglycemic episodes
have been described, as with SFT in other sites. The tumor
is usually located in deep tissue. Cross-sectional imaging
(CT-scan and MRI) reveals a heterogenous mass with avid
and heterogeneous enhancement after IV contrast admin-
istration in most cases [10]. Calciﬁcations were present
in fewer than 10% of benign or malignant SFT. Some
cases are called lipomatous SFT because some contain fat.
There is no distinctive radiological criterion for malignancy,
excluding the presence of distant metastases (present at
diagnosis in about 10–15% of cases) [10]. The criteria for
malignancy remain a topic of some debate. Malignant SFTs
are hypercellular and display at least focal moderate-to-
severe nuclear atypia. Malignant SFTs often have inﬁltrative
margins with surrounding tissues, have high mitotic count
(≥4 mitoses per 10 high-power ﬁelds), and display cellular
pleomorphism and tumor necrosis. The risk of metastasis is
estimated of about 25% [11].
En-bloc surgery is the recommended treatment for both
benign and malignant SFT. The risk of peroperative bleeding
had to be known. For SFT displaying criteria for malignancy,
adjuvant radiotherapy, when feasible is recommended by
analogy with other soft tissue sarcomas. There is no evidence
supporting the use of adjuvant chemotherapy. Long-term
follow is mandatory because of local or distant relapse in
malignant and considered benign SFT.
2.3. Meningeal Hemangiopericytoma (Solitary Fibrous Tu-
mor). Meningeal hemangioperictyoma (MHPC) constitutes
less than 2% of all meningeal tumors [15]. They have been
observed at the falx, occipital and spinal dura, tentorium
and cerebellopontine angle. They are ﬁrst considered as an
angioblastic form of meningioma [15]. WHO classiﬁcation
considers MHPC as a member of soft tissue sarcomas of
the central nervous system. MHPC is locally aggressive
and usually presents as dura-based masses and clinically
indistinguishable from to meningiomas. The median age
at diagnosis is about 40–50. The clinical and radiological
ﬁndings are not speciﬁc. Surgery remains the cornerstone
of the treatment, as other SFT family tumor. Tumor
hemorrhage is common during the surgical procedure, and
thus the standard of care today often includes preoperative
tumor embolisation [16]. Complete resection (R0) is fre-
quently diﬃcult to achieve because these tumors grow along
the sinuses. Adjuvant radiotherapy (50–60Gy) appears to
improve the local control rate [17, 18]. Conservative surgery
combined with adjuvant radiotherapy has been suggested
for tumor with unfavourable location [19]. In the Mena
series, local recurrence (2/3 of patients) and extracranial (1/3
of patients) metastases are frequent [20]. Bone, lung, and
liver are the most common metastases sites. Metastases could
appeared after a long period, usually 5–8 years or more,
sometimesmorethan20years[20,21].Classicaldoxorubicin
± ifosfamide-based chemotherapy has been disappointing in
the management of metastatic MHPC [18, 22]
2.4. Other Forms. SFT could occurred in any site (peritoneal,
intrahepatic,intrapulmonary,...).Thereisnorelevantspeci-
ﬁcity for such locations.
3. Focus onTumor Biology and
Systemic Treatment
3.1. Classical Chemotherapy. In a retrospective analysis
issued in 1978, Wong and Yogda have reported a response
of about 50% with doxorubicin-based regimens. This report
had to be interpreted with a great deal of caution because (i)
the diagnostic criteria were not well established at that time
and (ii) the sample size was limited to 16 patients [23]. In a
more recent report, Beadle and Hillcoat have reported their
experience of 4 patients treated with doxorubicin (50mg/m2
every 4 weeks) and dacarbazine (600–700mg/m2 every 4
weeks). Objective response was seen in 2 cases, stable disease
with symptoms relief in one case, and rapid progressiveSarcoma 3
disease in the fourth case [24]. Galanis et al. have found
a response rate of 1/7 in patients with meningeal MHPC
treated with doxorubicin-based regimens [22]. Park et al.
have reported in 2011 at the annual ASCO meetings their
retrospective single-center experience (1994–2007) with dif-
ferent chemotherapy regimens: classical doxorubicin-based
regimens (n = 15), gemcitabine (n = 4), and paclitaxel
(n = 4). The results appeared disappointing with a response
rate of 0/15 and a median progression-free survival of about
4 months [25]. Moreover, a case report shows an objective
response to trabectedin treatment in heavily pretreated
MHPC [26].
3.2. Temozolomide and Bevacizumab Combination. Park et
al. have reported in 2009 their experience with temo-
zolomide 150mg/m2 orally on days 1–7 and days 15–21
and bevacizumab 5mg/kg intravenously on days 8 and 22,
repeated at 28-day intervals in 14 patients (2005–2007). The
median number of cycles of temozolomide and bevacizumab
administered was 6.5 (2–20). Grade 3 to 4 toxicities were
mainly neutropenia and thrombocytopenia. Best response
assessment using so-called Choi criteria showed that 11/14
(79%) achieved a “Choi partial response” (PR), 2/14 (14%)
with stable disease (SD), and 1/14 (7%) developed progres-
sion of disease (PD). The median progression-free interval
was6(4–10)months.Thisreportsuggestedthatthisregimen
could be active and well-tolerated and that a formal phase II
trial was needed [27].
3.3. IGF2 Pathway. Several case reports demonstrated that
hypoglycemia is the consequence of insulin-like growth
factor 2 (IGF2) secretion [28–34] or other members of IGF
family or IGF protein binding [29]. IGF2 overexpression
seems to be the consequence of fetal promoter activation
and loss of imprinting in malignant SFT [28]. Hadju et al.
have conﬁrmed that IGF2 was uniformly detected in SFT
(23/23), regardless of anatomical location and was related to
loss of imprinting [35]. Paveli´ c et al. analyzed the expression
of the members of IGF in 7 SFT associated with severe
hypoglycemia and 12 cases without hypoglycemia. They
found that IGF1 receptor was expressed in 17/19 SFT. Other
members of the IGF network are frequently expressed: IGF1
(3/19), IGF2 (11/19), IGF-binding protein 1 (5/19), IGF-
binding protein 2 (3/19), and IGF-binding protein 3 (4/19)
(Paveli´ c et al. [36]). Hadju et al. did not ﬁnd mutation
of IGF-R(s) [35]. The in vitro inhibition of IGF1 receptor
is associated with inhibited proliferation [36]. This IGF
network plays a key role in SFT proliferation.
Large en-bloc resection resolves this paraneoplastic syn-
drome [2–4, 30, 31].
For tumor not amenable to surgery, symptomatic treat-
ment of hypoglycemia requires glucose intake, corticother-
apy, or glucagon administration [37]. One case report sug-
gests that radiotherapy could control hypoglycemic episodes
in locally advanced disease [38]. Embolisation had been
described as a palliative treatment for controlling these
manifestations [39]. Despite that SFT are labeled by 111
Indium-labelledoctreotidescintigraphy,somatostastinfailed
to ameliorate hypoglycemic episodes [38, 40]. Treatment
Table 1: The current partition of the old-term “hemangiopericy-
toma” (HPC).
True HPC, with
myoid/pericytic
diﬀerentiation
(i) HPC
(ii) Infantile HPC (infantile myoﬁbromatosis)
(iii) Glomangiopericytoma/myopericytoma
Solitary ﬁbrous
tumour (SFT)
group
(i) SFT
(ii) Giant cell angioﬁbroma
(iii) Lipomatous HPC
Other tumours
with HPC-like
features
(i) Synovial sarcoma with HPC-like features
with somatostatin does not provide response, either [41].
One patient with SFT enrolled in a phase-1 trial exploring
the association everolimus-ﬁgitumumab experienced partial
response [42].
3.4. Use of Tyrosine Kinase Inhibitors. Several case reports
and retrospective studies suggest that imatinib [43, 44],
sorafenib [45], and sunitinib [45, 46]c o u l dp r o v i d el o n g -
lasting stable disease. Tumours responding to imatinib
strongly and diﬀusely expressed PDGFR-alpha, PDGRFR-
beta [13, 45]. Rossi et al. described a case with missense
mutation on exon 18 of the PDGFR-beta gene [44]. In
the Italian experience (10 patients treated with sunitinib),
the best response according to the Choi criteria was six
partial responses (all with response evaluation criteria in
solid tumors stable disease), one stable disease, and three
progressive diseases. Evidence of beneﬁt lasted >6 months
in ﬁve patients [46]. In France, a phase-II trial investigating
activity and safety of sorafenib is ongoing. Five patients with
progressive disease at study entry have been already enrolled.
4. SFT in Children
Paediatric cases of STF are exceptionally reported [13].
The literature review shows only a few paediatric case
reports occurring either in Pleura in a 7-year-old boy [13],
in Mesentery in a 6-year-old boy [14], or in Orbit [12].
Characteristics of these 3 cases are summarized in Table 1.
These 3 tumours presented as nodular, well-encapsulated
masses with vascularised component are all diagnosed
on morphology and immunohistochemical proﬁle (CD34
positivity) (Table 2).
It is important to ﬁrst exclude some diﬀerential diagnosis
among the highly vascular spindle-cell tumours occurring
in children: synovial sarcomas, infantile myoﬁbromatosis,
and Darrier Ferrand dermatoﬁbrosarcoma (a CD34 positive
tumor is also to be excluded in cutaneous or subcutaneous
location).
MostoftenSFTsareregardedasbenignbutthebehaviour
is unpredictable only on morphological criteria and there
is no strict correlation between morphology and behaviour.
Thus long-term followup is mandatory. In the paediatric
group, metastatic dissemination is also described [14].
According to the previous reports, outcome depends on
the completeness of the tumour resection. Large en-bloc4 Sarcoma
Table 2: Characteristics of the paediatric cases reported in the literature.
Ref. Location Age Size macroscopic aspect Histology and immunohistochemistry Outcome
[12]M e s e n t e r y 6 y . o .
10 × 8 × 7cm
Well-deﬁned solid mass
Encapsulated tumor
Solid and cystic parts
Uniform hypercellular areas of
pleomorphic spindle cells intermixed
with a dense collagenous stroma with few
necrotic areas.
25 mitoses per 50HPF
(i) CD34 positive
(ii) NSE positive
(iii) DOG-1, Bcl-2, CD117, desmin,
S-100 protein, and SMA negative.
No lymph node
metastasis was
present at
diagnosis.
Liver metastasis
after 8 months
[13]P l e u r a 7 y . o .
5 × 5 × 4cm
Well-demarcated
nodular mass
Low cellularity
(i) CD34, vimentin and bcl2, positive
(ii) Cytokeratin, SMA, desmin, and
S100 negative
No metastasis.
No evidence of
tumor
recurrence 9
months later
[14]O r b i t 1 5 y . o .
1.5 × 1.4 × 1.0cm
Well-circumscribed
mass
Highly vascular
Highly cellular spindle tumor
2m i t o s e sp e r2 0H P F
(i) AE1/AE2 cytokeratin,
smooth-muscle actin, muscle-speciﬁc
actin, desmine, S100 negative
(ii) CD34. and vimentin positive
No metastasis
No recurrence
after local
radiotherapy
resection and achievement of clear margin reduce the risk
of local relapse [4]. SFTs are regarded as chemoresistant
tumours [23–27]. But, regarding the lack of data and the
rarity of this entity in paediatric populations, the treatment
recommendation can only be deduced from adult literature.
5. Conclusions
HPC is a controversial entity. SFT could be benign or
malignant; criteria for malignancy are discussed. En-bloc
resection remains the cornerstone of therapy for curative
intent. For tumor displaying evident criteria for malignancy,
adjuvant radiotherapy had to be considered. Local and
distant relapse can occur more than 20 years after the
initial treatment. The activity of classical chemotherapy
appears disappointing. Hypoglycemic episodes appear to be
explained by activation of IGFR1, perhaps through excess
IGF2 signaling. The IGF1R pathway appears to be an impor-
tant axis stimulating SFT proliferation. The combination
temozolomide-bevacizumab and tyrosine kinase inhibitor
actingon VEGF receptors or PDGF receptors warrant formal
p h a s eI It r i a l s .
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